Regenerx Biopharmaceuticals Inc (RGRX) SEC Filing 8-K Material Event for the period ending Wednesday, February 27, 2019

Regenerx Biopharmaceuticals Inc

CIK: 707511 Ticker: RGRX

View differences made from one to another to evaluate Regenerx Biopharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Regenerx Biopharmaceuticals Inc.


Assess how Regenerx Biopharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Regenerx Biopharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Regenerx Biopharmaceuticals Inc provided additional information to their SEC Filing as exhibits

Ticker: RGRX
CIK: 707511
Form Type: 8-K Corporate News
Accession Number: 0001144204-19-012259
Submitted to the SEC: Tue Mar 05 2019 4:53:26 PM EST
Accepted by the SEC: Tue Mar 05 2019
Period: Wednesday, February 27, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement
  3. New Financial Obligation
  4. Other Events
  5. Security Holders Change
  6. Unregistered Sales

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: